Division of Endocrinology, Diabetes, Nutrition, and Metabolism, Mayo Clinic, Rochester, MN 55905, USA.
Division of Endocrinology, Diabetes, Nutrition, and Metabolism, Mayo Clinic, Rochester, MN 55905, USA
BMJ. 2015 Sep 2;351:h3783. doi: 10.1136/bmj.h3783.
Osteoporosis is a systemic skeletal disorder characterized by bone loss, which leads to impaired bone strength and an increased risk of fractures. Two million fractures are attributed to osteoporosis annually in the United States and they are associated with serious morbidity and mortality. Bisphosphonates reduce the risk of fracture by suppressing bone resorption and increasing bone strength, and they have been widely used for the prevention and treatment of osteoporosis. However, the use of these drugs for the management of osteoporosis remains a clinical challenge. There are several important considerations including appropriate patient selection, pretreatment evaluation, potential adverse effects, patient preferences, and adherence. This review will discuss the evidence informing the clinical strategy for using bisphosphonates in patients with osteoporosis and those at high risk of fracture, focusing on the benefits and risks of treatment. We will also consider issues related to the monitoring and duration of treatment.
骨质疏松症是一种以骨量丢失为特征的全身性骨骼疾病,可导致骨强度受损,骨折风险增加。在美国,每年有 200 万例骨折与骨质疏松症有关,这些骨折与严重的发病率和死亡率相关。双膦酸盐通过抑制骨吸收和增加骨强度来降低骨折风险,已广泛用于骨质疏松症的预防和治疗。然而,这些药物在骨质疏松症管理中的应用仍然是一个临床挑战。有几个重要的考虑因素,包括适当的患者选择、治疗前评估、潜在的不良反应、患者偏好和依从性。这篇综述将讨论关于骨质疏松症患者和高骨折风险患者使用双膦酸盐的临床策略的证据,重点是治疗的益处和风险。我们还将考虑与监测和治疗持续时间相关的问题。